Efficacy and Safety of Tezepelumab in Patients with Eosinophilic Esophagitis - CROSSING

Study identifier:D5244C00001

ClinicalTrials.gov identifier:NCT05583227

EudraCT identifier:2022-001294-31

CTIS identifier:2023-504277-20-00

Recruiting

Official Title

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING).

Medical condition

Eosinophilic Esophagitis

Phase

Phase 3

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

360

Study type

Interventional

Age

12 Years - 80 Years

Date

Study Start Date: 10 Nov 2022
Estimated Primary Completion Date: 01 May 2026
Estimated Study Completion Date: 08 Jan 2027

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Amgen

Inclusion and exclusion criteria